These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1251 related items for PubMed ID: 17592153

  • 1. Fusion of metabolic function and morphology: sequential [18F]fluorodeoxyglucose positron-emission tomography/computed tomography studies yield new insights into the natural history of bone metastases in breast cancer.
    Du Y, Cullum I, Illidge TM, Ell PJ.
    J Clin Oncol; 2007 Aug 10; 25(23):3440-7. PubMed ID: 17592153
    [Abstract] [Full Text] [Related]

  • 2. Circulating tumor cells and [18F]fluorodeoxyglucose positron emission tomography/computed tomography for outcome prediction in metastatic breast cancer.
    De Giorgi U, Valero V, Rohren E, Dawood S, Ueno NT, Miller MC, Doyle GV, Jackson S, Andreopoulou E, Handy BC, Reuben JM, Fritsche HA, Macapinlac HA, Hortobagyi GN, Cristofanilli M.
    J Clin Oncol; 2009 Jul 10; 27(20):3303-11. PubMed ID: 19451443
    [Abstract] [Full Text] [Related]

  • 3. Detection of occult bone metastases from head and neck squamous cell carcinoma: impact of positron emission tomography computed tomography with fluorodeoxyglucose F 18.
    Basu D, Siegel BA, McDonald DJ, Nussenbaum B.
    Arch Otolaryngol Head Neck Surg; 2007 Aug 10; 133(8):801-5. PubMed ID: 17709620
    [Abstract] [Full Text] [Related]

  • 4. Positron emission tomography/computed tomography with 18fluoro-deoxyglucose in the detection of local recurrence and distant metastases of pediatric sarcoma.
    Arush MW, Israel O, Postovsky S, Militianu D, Meller I, Zaidman I, Sapir AE, Bar-Shalom R.
    Pediatr Blood Cancer; 2007 Dec 10; 49(7):901-5. PubMed ID: 17252575
    [Abstract] [Full Text] [Related]

  • 5. Prospective comparison of [18F]fluorodeoxyglucose positron emission tomography and computed tomography in patients with melanoma with palpable lymph node metastases: diagnostic accuracy and impact on treatment.
    Bastiaannet E, Wobbes T, Hoekstra OS, van der Jagt EJ, Brouwers AH, Koelemij R, de Klerk JM, Oyen WJ, Meijer S, Hoekstra HJ.
    J Clin Oncol; 2009 Oct 01; 27(28):4774-80. PubMed ID: 19720925
    [Abstract] [Full Text] [Related]

  • 6. Increased (18)F-fluorodeoxyglucose uptake in benign, nonphysiologic lesions found on whole-body positron emission tomography/computed tomography (PET/CT): accumulated data from four years of experience with PET/CT.
    Metser U, Even-Sapir E.
    Semin Nucl Med; 2007 May 01; 37(3):206-22. PubMed ID: 17418153
    [Abstract] [Full Text] [Related]

  • 7. Detection of hematogenous bone metastasis in cervical cancer: 18F-fluorodeoxyglucose-positron emission tomography versus computed tomography and magnetic resonance imaging.
    Liu FY, Yen TC, Chen MY, Lai CH, Chang TC, Chou HH, Hong JH, Chen YR, Ng KK.
    Cancer; 2009 Dec 01; 115(23):5470-80. PubMed ID: 19739235
    [Abstract] [Full Text] [Related]

  • 8. F-18 FDG PET/CT in the management of thyroid cancer.
    Iagaru A, Kalinyak JE, McDougall IR.
    Clin Nucl Med; 2007 Sep 01; 32(9):690-5. PubMed ID: 17710020
    [Abstract] [Full Text] [Related]

  • 9. [The role of whole body 2-[fluorine-18]-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography in the management of unknown primary tumors].
    Wu ZJ, Zhang YX, Wei H, Jia Q.
    Zhonghua Yi Xue Za Zhi; 2007 Aug 28; 87(32):2253-6. PubMed ID: 18001544
    [Abstract] [Full Text] [Related]

  • 10. Noninvasive diagnosis of solitary pulmonary lesions in cancer patients based on 2-fluoro-2-deoxy-D-glucose avidity on positron emission tomography/computed tomography.
    Bar-Shalom R, Kagna O, Israel O, Guralnik L.
    Cancer; 2008 Dec 01; 113(11):3213-21. PubMed ID: 18924145
    [Abstract] [Full Text] [Related]

  • 11. Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization.
    Basu S, Chen W, Tchou J, Mavi A, Cermik T, Czerniecki B, Schnall M, Alavi A.
    Cancer; 2008 Mar 01; 112(5):995-1000. PubMed ID: 18098228
    [Abstract] [Full Text] [Related]

  • 12. [The role of 18F-FDG SPECT-CT in detecting recurrence and metastases in breast cancer patients with elevated tumor markers].
    Xing Y, Zhao JH, Wang TS, Qiao WL, Che WJ.
    Zhonghua Zhong Liu Za Zhi; 2009 Feb 01; 31(2):129-33. PubMed ID: 19538891
    [Abstract] [Full Text] [Related]

  • 13. F-18 FDG PET/CT evaluation of osseous and soft tissue sarcomas.
    Iagaru A, Quon A, McDougall IR, Gambhir SS.
    Clin Nucl Med; 2006 Dec 01; 31(12):754-60. PubMed ID: 17117068
    [Abstract] [Full Text] [Related]

  • 14. Physiologic thymic uptake of 18F-FDG in children and young adults: a PET/CT evaluation of incidence, patterns, and relationship to treatment.
    Jerushalmi J, Frenkel A, Bar-Shalom R, Khoury J, Israel O.
    J Nucl Med; 2009 Jun 01; 50(6):849-53. PubMed ID: 19443604
    [Abstract] [Full Text] [Related]

  • 15. 18F-FDG PET and PET/CT for detection of pulmonary metastases from musculoskeletal sarcomas.
    Iagaru A, Chawla S, Menendez L, Conti PS.
    Nucl Med Commun; 2006 Oct 01; 27(10):795-802. PubMed ID: 16969262
    [Abstract] [Full Text] [Related]

  • 16. The detection of bone metastases in patients with high-risk prostate cancer: 99mTc-MDP Planar bone scintigraphy, single- and multi-field-of-view SPECT, 18F-fluoride PET, and 18F-fluoride PET/CT.
    Even-Sapir E, Metser U, Mishani E, Lievshitz G, Lerman H, Leibovitch I.
    J Nucl Med; 2006 Feb 01; 47(2):287-97. PubMed ID: 16455635
    [Abstract] [Full Text] [Related]

  • 17. PET/CT detection of unexpected gastrointestinal foci of 18F-FDG uptake: incidence, localization patterns, and clinical significance.
    Israel O, Yefremov N, Bar-Shalom R, Kagana O, Frenkel A, Keidar Z, Fischer D.
    J Nucl Med; 2005 May 01; 46(5):758-62. PubMed ID: 15872347
    [Abstract] [Full Text] [Related]

  • 18. Prevention of brown adipose tissue activation in 18F-FDG PET/CT of breast cancer patients receiving neoadjuvant systemic therapy.
    Aukema TS, Vogel WV, Hoefnagel CA, Valdés Olmos RA.
    J Nucl Med Technol; 2010 Mar 01; 38(1):24-7. PubMed ID: 20159933
    [Abstract] [Full Text] [Related]

  • 19. 18F-FDG PET/CT, 99mTc-MIBI, and MRI in evaluation of patients with multiple myeloma.
    Fonti R, Salvatore B, Quarantelli M, Sirignano C, Segreto S, Petruzziello F, Catalano L, Liuzzi R, Rotoli B, Del Vecchio S, Pace L, Salvatore M.
    J Nucl Med; 2008 Feb 01; 49(2):195-200. PubMed ID: 18199607
    [Abstract] [Full Text] [Related]

  • 20. Effect of (18)F-FDG PET/CT imaging in patients with clinical Stage II and III breast cancer.
    Groheux D, Moretti JL, Baillet G, Espie M, Giacchetti S, Hindie E, Hennequin C, Vilcoq JR, Cuvier C, Toubert ME, Filmont JE, Sarandi F, Misset JL.
    Int J Radiat Oncol Biol Phys; 2008 Jul 01; 71(3):695-704. PubMed ID: 18436392
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 63.